EyePoint EYPT
EyePoint, Inc. · Nasdaq · Laboratory Analytical Instruments
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 18, 2026 | Karen L. Zaderej director | Bought | 10,600 | $4.93 | $52,258 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 16 →Results of operations and financial condition · Costs of exit or disposal activities · Other events · Financial statements and exhibits
AI summary, unreviewedEyePoint cuts 53% of workforce and ends wet AMD Phase 3 early after LUCIA miss, pivots to DME with ~$30 million annualized savings
Other events · Financial statements and exhibits
AI summary, unreviewedEyePoint's DURAVYU misses primary non-inferiority endpoint in LUCIA Phase 3 wet AMD trial, a second miss after LUGANO
Other events · Financial statements and exhibits